SynthesisFrontiers in microbiology2026
Population pharmacokinetic model for meropenem in pediatric patients: a systematic review.
Synthesis in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pharmacokinetics of meropenem in pediatric patients have large interindividual variability. Model-informed precision dosing (MIPD) is a promising way to ensure optimal exposure but relies on a population pharmacokinetic (PPK) model. This review systemically synthesized the available PPK model for meropenem in pediatric patients to facilitate MIPD in these patients. Methods: Four electronic databases were searched for eligible studies that reported the use of the meropenem PPK model for pediatric patients. The study design information, patient characteristic demography, PPK modeling strategy and final PPK parameter estimates were extracted and reviewed. Results: Twenty studies published from 2006 to 2025 were included in the analysis. Fourteen studies had prospective designs, and four studies were international multicenter studies. Seven studies applied an intensive sampling strategy. Pediatric patients with various characteristics were included, and most had severe infections or were admitted to the ICU. Four studies focused on patients with organ support, mainly renal replacement and extracorporeal membrane oxygenation. The sample sizes were usually small (sample sizes no more than 50). Fourteen studies ultimately obtained the 2-CMT model, and the remaining studies used the 1-CMT model, except for one 3-CMT model. Body weight, age and renal function indicators were the most common covariates. The typical CL values ranged from 0.50-13.22 L/h or 0.122-0.526 L/h/kg. The Vcs for the 2-CMT models ranged from 0.969-21.4 L or 0.272-0.57 L/kg. Most models underwent internal validation, but only one study performed external validation. Conclusion: This study successfully integrated the current meropenem PPK models for pediatric patients, which would benefit the clinical application of MIPD. Clinicians should select appropriate models on the basis of patient characteristics carefully, and therapeutic drug monitoring is important at the current stage. External validation and well-designed studies on specific subpopulations, such as patients with organ support, neonates, and specific disease status, are needed. Systematic review registration: PROSPERO, identifier (CRD420261481301).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.